Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review

Purpose In July 2007, the Centers for Medicare and Medicaid Services (CMS) limited coverage of erythropoiesis-stimulating agents (ESAs) in cancer patients with chemotherapy-induced anemia (CIA) through a National Coverage Determination (NCD). The primary objective of this study was to compare transf...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2012-09, Vol.20 (9), p.2089-2096
Main Authors: Henry, David H., Langer, Corey J., McKenzie, R. Scott, Piech, Catherine Tak, Senbetta, Mekré, Schulman, Kathy L., Stepanski, Edward J.
Format: Article
Language:English
Subjects:
Aged
Anemia
Anemia - chemically induced
Blood Transfusion - utilization
Blood transfusions
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Cancer
Centers for Medicare and Medicaid Services (U.S.)
Chemotherapy
Colorectal Neoplasms - blood
Colorectal Neoplasms - drug therapy
Drug therapy
Erythropoiesis - drug effects
Female
Hemoglobin
Hemoglobins - analysis
Humans
Insurance Coverage
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Male
Medical Audit
Medicine
Medicine & Public Health
Middle Aged
Neoplasms - blood
Neoplasms - drug therapy
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Rehabilitation Medicine
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose In July 2007, the Centers for Medicare and Medicaid Services (CMS) limited coverage of erythropoiesis-stimulating agents (ESAs) in cancer patients with chemotherapy-induced anemia (CIA) through a National Coverage Determination (NCD). The primary objective of this study was to compare transfusion rates in patients with CIA with lung, breast, or colorectal cancer before and after the NCD. Methods Adult Medicare patients with CIA treated at 49 community oncology clinics were selected from two time periods based on clinics' NCD implementation date. Chart data were abstracted for 12 weeks post-CIA episode start, defined as hemoglobin (Hb) level
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-011-1318-2